Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00008268 · ClinicalTrials.gov registry record · Phase 2
Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00008268: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00008268 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00008268, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Melphalan and colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase II trial to study the effectiveness of melphalan combined with filgrastim in stimulating peripheral stem cells in patients who have multiple myeloma.
Interventions
- DRUG melphalan
- BIOLOGICAL filgrastim
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-08 |
| Est. Completion | 2003-06 |
| Phase | Phase 2 |
What the finished NCT00008268 record still lists
NCT00008268 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which melphalan is the first listed.
NCT00008268 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00008268 about?
NCT00008268 is a clinical study titled "Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma". RATIONALE: Melphalan and colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase II trial to study the effectiveness of melphalan combined with filgrastim in stimulating peripheral stem cells in patients who have...
What is the current status of trial NCT00008268?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-08. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00008268?
The interventions under investigation include: melphalan (DRUG), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00008268?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia